Changeflow GovPing Pharma & Drug Safety CD3-specific binding molecules
Routine Notice Added Final

CD3-specific binding molecules

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO granted Immunocore Limited Patent US12590152B2 covering CD3-specific binding molecules, specifically antibodies and fragments with improved properties. The patent contains 19 claims and names 8 inventors including Martina Canestraro and Stephen Harper. This is a routine patent grant establishing intellectual property rights without regulatory compliance obligations.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO issued Patent US12590152B2 to Immunocore Limited on March 31, 2026, covering CD3-specific binding molecules—antibodies and fragments with improved properties—based on Application No. 17427592 filed January 30, 2020. The patent is classified under CPC codes C07K 16/2809 and related peptide/antibody categories.

Patent holders receive enforceable exclusive rights to practice the claimed invention in the US. The public cannot practice the patented invention without authorization. This is a routine intellectual property action that does not impose compliance deadlines or regulatory requirements on third parties. Competitors developing CD3-binding therapeutics should review the claims for potential infringement concerns.

Archived snapshot

Mar 31, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

CD3-specific binding molecules

Grant US12590152B2 Kind: B2 Mar 31, 2026

Assignee

IMMUNOCORE LIMITED

Inventors

Martina Canestraro, Nele Dieckmann, Stephen Harper, Peter Benedict Kirk, Rachel Mulvaney, Ronan O'Dwyer, Ian Butler Robertson

Abstract

The present invention relates to specific binding molecules which bind to CD3, particularly antibodies and fragments thereof, with improved properties.

CPC Classifications

C07K 16/2809 C07K 2317/24 C07K 2317/31 C07K 2317/565 C07K 2317/567 C07K 2317/622 C07K 2317/73 C07K 2317/92 C07K 2319/00 C07K 14/7051 C07K 16/30 C07K 2317/70 A61K 2039/505

Filing Date

2020-01-30

Application No.

17427592

Claims

19

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 31st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12590152B2

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent Grants Intellectual Property
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!